Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) containing firefly luciferase mRNA. Firefly luciferase mRNA-LNP exhibits a stable nanostructure, in which LNP plays a key role in effectively protecting and transporting mRNA to cells. Luciferase is a bioluminescent reporter gene for gene regulation and functional studies. Firefly Luciferase mRNA-LNP expresses firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Firefly luciferase mRNA-LNP is studied in research for RNA delivery, cell viability, and translation efficiency.
eGFP mRNA-LNP (500 ng/μL) is a lipid nanoparticle (LNP) containing eGFP mRNA. eGFP mRNA-LNP carries Enhanced Green Fluorescent Protein (eGFP), which will express green fluorescent protein after entering the cell. eGFP is commonly used as a reporter gene detectable by fluorescence microscopy or flow cytometry (excitation wavelength = 488 nm; emission wavelength = 535/40 bandpass). eGFP mRNA-LNP can be used for RNA delivery, translation efficiency and cell viability.
COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein. COVID-19 Spike Protein undertakes the functions of virus binding with host cell receptors, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design. COVID-19 Spike Protein mRNA-LNP can be used for RNA delivery, vaccine formulation and design targeting SARS-CoV-2.
eGFP circRNA-LNP is a lipid nanoparticle (LNP) containing eGFP circRNA, suitable for assays of RNA delivery, translation efficiency, cell viability, etc. eGFP circRNA carries Enhanced Green Fluorescent Protein (Enhanced Green Fluorescent Protein) eGFP, which will express green fluorescent protein after entering the cell. eGFP is commonly used as a reporter gene detectable by fluorescence microscopy or flow cytometry.
Doxorubicin liposome is a liposome-encapsulated form of doxorubicin hydrochloride (HY-15142). Doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic, is a potent human DNA topoisomerase I and topoisomerase II inhibitor. Compared to traditional doxorubicin, liposome encapsulation reduces its cardiotoxicity and prolongs its circulation time, thus enabling it to effectively target tumor tissue.
Liposomal Coenzyme Q10 is an orally effective delivery system that encapsulates fat-soluble Coenzyme Q10 (CoQ10) (HY-N0111) via liposomal nanocarriers. Liposomal Coenzyme Q10 alleviates hepatic oxidative stress, attenuates hepatic inflammatory responses, reduces hepatocyte apoptosis, and ameliorates liver fibrosis. Liposomal Coenzyme Q10 activates the ferroptosis suppressor protein 1 (FSP1)/Coenzyme Q10 system, reduces the accumulation of malondialdehyde and ROS, and inhibits neuronal ferroptosis. Liposomal Coenzyme Q10 can be used in studies related to Propanoic acid (HY-W020017)-induced liver injury and subarachnoid hemorrhage.
Paclitaxel liposome (Liposomal paclitaxel) is a liposome-encapsulated form of Paclitaxel (HY-B0015). Paclitaxel is a natural antitumor agent that stabilizes tubulin polymerization. Paclitaxel liposome exhibits reduced acute toxicity, prolonged circulating half-life of paclitaxel, and enhanced accumulation at tumor sites. Paclitaxel liposome can be used in cancer-related research.
Liposomal Curcumin is a specialized delivery system that encapsulates Curcumin (HY-N0005) within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of Curcumin. Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin is a photosensitizer against microorganisms. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.
The product size below only indicate the effective content of Curcumin.
Anionic Liposomes (DOPG:DOPC (90:10 molar ratio, 10 mM)) is a type of artificial lipid vesicle with strong negative charge (Liposome), composed of 90% DOPG (HY-142980) and 10% DOPC. DOPG is a phosphatidylglycerol composed of unsaturated fatty acids (oleoyl groups), providing negative charges and membrane fluidity. DOPC acts as a neutral matrix lipid, mainly used to maintain the integrity and appropriate fluidity of the lipid bilayer, and does not change the net charge itself.
- Formula: C36H42N4O15
- Molecular Weight: 770.74
Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia.
Amikacin liposome is a liposome-encapsulated form of Amikacin disulfate (HY-B0509B), an aminoglycoside antibiotic with antibactericidal avtivity. Amikacin liposome prolongs the release of amikacin in the lungs and reduces systemic exposure, thereby lowering systemic toxicity.
Cisplatin liposome is a liposome-encapsulated form of Cisplatin (HY-17394). Cisplatin (CDDP) is an anti-tumor chemotherapeutic agent that cross-links with DNA, causing DNA damage in cancer cells. Cisplatin liposome prolongs drug circulation time and slowly releases the drug, allowing it to accumulate in the tumor and exert its killing effect.
Mitoxantrone hydrochloride liposome is a liposome-encapsulated Mitoxantrone hydrochloride (HY-13502A) (a topoisomerase II inhibitor). Compared to regular Mitoxantrone hydrochloride, Mitoxantrone hydrochloride liposome enhances antitumor activity and prolongs drug circulation time in the body.
Bupivacaine liposome is a liposome-encapsulated form of Bupivacaine (HY-B0405). Bupivacaine is an NMDA receptor inhibitor. During the action potential, Bupivacaine blocks sodium channels, thereby inhibiting the generation and conduction of nerve impulses induced by painful stimuli. Bupivacaine liposome reduces the release rate of Bupivacaine, thus achieving a long-lasting pain relief effect.
Liposomal verteporfin is a liposome-encapsulated form of Verteporfin (HY-B0146). Verteporfin is a photosensitizer used in photodynamic therapy, which generates reactive oxygen species (ROS) upon irradiation at 690 nm to mediate photodynamic effects. Liposomal verteporfin can promote the release of Oxaliplatin (HY-17371) from endolysosomes via photochemical internalization (PCI), prolong the drug circulation time and enable sustained release, accumulate the drug in neovascular vessels, and enhance its cytotoxicity in tumor models. Liposomal verteporfin can be used in studies related to neovascular eye diseases and pancreatic cancer[1][2][3].
